89Zr-oxine complex PET cell imaging in monitoring cell-based therapies

Radiology

Volumn 275, Issue 2, 2015, Pages 490-500

  Sato, Noriko ^a   Wu, Haitao ^b   Asiedu, Kingsley O ^a   Szajek, Lawrence P ^c   Griffiths, Gary L ^d   Choyke, Peter L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXINE ZR 89; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 8 QUINOLINOL; ISOTOPE; ZIRCONIUM;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; BONE MARROW CELL; CELL FUNCTION; CELL LABELING; CELL PROLIFERATION; CELL SURVIVAL; CELL THERAPY; CELL TRACKING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG SYNTHESIS; IMMUNOTHERAPY; IN VITRO STUDY; ISOTOPE LABELING; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CELL TRANSPLANTATION; CELLS; EVALUATION STUDY; PHYSIOLOGIC MONITORING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING;

ANIMALS; CELL TRACKING; CELL TRANSPLANTATION; CELLS; ISOTOPES; MICE; MICE, INBRED C57BL; MONITORING, PHYSIOLOGIC; OXYQUINOLINE; POSITRON-EMISSION TOMOGRAPHY; ZIRCONIUM;

EID: 84928990953     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.15142849     Document Type: Article

References (36)

1. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12(4):265-277.
2. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004;104(8):2235-2246.
3. Kater AP, van Oers MH, Kipps TJ. Cellular immune therapy for chronic lymphocytic leukemia. Blood 2007;110(8):2811-2818.
4. Körbling M, Freireich EJ. Twenty-five years of peripheral blood stem cell transplantation. Blood 2011;117(24):6411-6416.
5. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368(16):1509-1518.
6. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013;3(4):388-398.
7. Shi H, Liu L, Wang Z. Improving the efficacy and safety of engineered T cell therapy for cancer. Cancer Lett 2013;328(2):191-197.
8. Bachy E, Coiffier B. Anti-PD1 antibody: a new approach to treatment of lymphomas. Lancet Oncol 2014;15(1):7-8.
9. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014;15(1):69-77.
10. Choy G, Choyke P, Libutti SK. Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol Imaging 2003;2(4):303-312.
11. Wang X, Rosol M, Ge S, et al. Dynamic tracking of human hematopoietic stem cell engraftment using in vivo bioluminescence imaging. Blood 2003;102(10):3478-3482.
12. Limberis MP, Bell CL, Wilson JM. Identification of the murine firefly luciferase-specific CD8 T-cell epitopes. Gene Ther 2009;16(3): 441-447.
13. de Vries IJ, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005;23(11): 1407-1413.
14. Kadayakkara DK, Korrer MJ, Bulte JW, Levitsky HI. Paradoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging. Cancer Res 2015;75(1):51-61.
15. Kircher MF, Allport JR, Graves EE, et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res 2003;63(20):6838-6846.
16. Ahrens ET, Zhong J. In vivo MRI cell tracking using perfluorocarbon probes and fluorine-19 detection. NMR Biomed 2013;26(7):860-871.
17. Barnett BP, Ruiz-Cabello J, Hota P, et al. Use of perfluorocarbon nanoparticles for non-invasive multimodal cell tracking of human pancreatic islets. Contrast Media Mol Imaging 2011;6(4):251-259.
18. Srinivas M, Turner MS, Janjic JM, Morel PA, Laidlaw DH, Ahrens ET. In vivo cytometry of antigen-specific t cells using 19F MRI. Magn Reson Med 2009;62(3):747-753.
19. Temme S, Bönner F, Schrader J, Flögel U. 19F magnetic resonance imaging of endogenous macrophages in inflammation. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2012;4(3):329-343.
20. Thakur ML, Coleman RE, Welch MJ. Indium- 111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs. J Lab Clin Med 1977;89(1):217-228.
21. McAfee JG, Thakur ML. Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. I. Soluble agents. J Nucl Med 1976;17(6):480-487.
22. Roca M, de Vries EF, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with (111)In-oxine. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging 2010;37(4):835-841. [Published correction appears in Eur J Nucl Med Mol Imaging 2010;37(6):1234.]
23. Coakley AJ, Mountford PJ. 99mTc-HMPAO for labelling leucocytes in infection. Lancet 1987;1(8523):44.
24. Peters AM, Danpure HJ, Osman S, et al. Clinical experience with 99mTc-hexamethylpropylene- amineoxime for labelling leucocytes and imaging inflammation. Lancet 1986;2(8513):946-949.
25. de Vries EF, Roca M, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with (99m)Tc-HMPAO. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging 2010;37(4):842-848.
26. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun 2008;29(3):193-207.
27. Botti C, Negri DR, Seregni E, et al. Comparison of three different methods for radiolabelling human activated T lymphocytes. Eur J Nucl Med 1997;24(5):497-504.
28. Wolfs E, Struys T, Notelaers T, et al. 18FFDG labeling of mesenchymal stem cells and multipotent adult progenitor cells for PET imaging: effects on ultrastructure and differentiation capacity. J Nucl Med 2013;54(3): 447-454.
29. Brown DM, Fisher TL, Wei C, Frelinger JG, Lord EM. Tumours can act as adjuvants for humoral immunity. Immunology 2001;102(4): 486-497.
30. Szajek L, Barker W, Shielah C, Plascjak P. Targetry, semi-remote processing, and quality control for routine production of Zr-89 for PET studies. J Nucl Med 2013;54(Suppl 2): 1015.
31. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specificactivity zirconium-89. Nucl Med Biol 2009; 36(7):729-739.
32. Kathirgamanathan P, Surendrakumar S, Antipan-Lara J, et al. Discovery of two new phases of zirconium tetrakis(8-hydroxyquinolinolate): synthesis, crystal structure and their electron transporting characteristics in organic light emitting diodes (OLEDs). J Mater Chem 2011;21(6):1762-1771.
33. Charoenphun P, Meszaros LK, Chuamsaamarkkee K, et al. [(89)Zr]Oxinate4 for long-term in vivo cell tracking by positron emission tomography. Eur J Nucl Med Mol Imaging 2015;42(2):278-287.
34. Thakur ML, Segal AW, Louis L, Welch MJ, Hopkins J, Peters TJ. Indium-111-labeled cellular blood components: mechanism of labeling and intracellular location in human neutrophils. J Nucl Med 1977;18(10):1022-1026.
35. Pantin JM, Hoyt RF Jr, Aras O, et al. Optimization of intrabone delivery of hematopoietic progenitor cells in a swine model using cell radiolabeling with [89]zirconium. Am J Transplant 2015 Feb 5. [Epub ahead of print]
36. Abou DS, Ku T, Smith-Jones PM. In vivo biodistribution and accumulation of 89Zr in mice. Nucl Med Biol 2011;38(5):675-681.